AAAAAA

   
Results: 1-8 |
Results: 8
Re: Tumor characteristics and clinical outcome of elderly women with breast cancer - Response
Authors: Diab, SG Elledge, RM Clark, GM
Citation: Sg. Diab et al., Re: Tumor characteristics and clinical outcome of elderly women with breast cancer - Response, J NAT CANC, 93(1), 2001, pp. 65-66
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclearreceptor-interacting protein with both coactivator and corepressor functions
Authors: Zhao, HH Herrera, RE Coronado-Heinsohn, E Yang, MC Ludes-Meyers, JH Seybold-Tilson, KJ Nawaz, Z Yee, D Barr, FG Diab, SG Brown, PH Fuqua, SAW Osborne, CK
Citation: Hh. Zhao et al., Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclearreceptor-interacting protein with both coactivator and corepressor functions, J BIOL CHEM, 276(30), 2001, pp. 27907-27912
Tumor characteristics and clinical outcome of elderly women with breast cancer
Authors: Diab, SG Elledge, RM Clark, GM
Citation: Sg. Diab et al., Tumor characteristics and clinical outcome of elderly women with breast cancer, J NAT CANC, 92(7), 2000, pp. 550-556
Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies
Authors: Hidalgo, M Villalona-Calero, MA Eckhardt, SG Drengler, RL Rodriguez, G Hammond, LA Diab, SG Weiss, G Garner, AM Campbell, E Davidson, K Louie, A O'Neil, JD von Borstel, R Von Hoff, DD Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies, J CL ONCOL, 18(1), 2000, pp. 167-177
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
Authors: Britten, CD Rowinsky, EK Baker, SD Agarwala, SS Eckardt, JR Barrington, R Diab, SG Hammond, LA Johnson, T Villalona-Calero, M Fraass, U Statkevich, P Von Hoff, DD Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, CLIN CANC R, 5(7), 1999, pp. 1629-1637
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors
Authors: Diab, SG Baker, SD Joshi, A Burris, HA Cobb, PW Villalona-Calero, RA Eckhardt, SG Weiss, GR Rodriguez, GI Drengler, R Kraynak, M Hammond, L Finizio, M Von Hoff, DD Rowinsky, EK
Citation: Sg. Diab et al., A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors, CLIN CANC R, 5(2), 1999, pp. 299-308
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system
Authors: Diab, SG Hilsenbeck, SG Izbicka, E Weitman, SD Von Hoff, DD
Citation: Sg. Diab et al., Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system, ANTI-CANC D, 10(3), 1999, pp. 303-307
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas
Authors: Diab, SG Clark, GM Osborne, CK Libby, A Allred, DC Elledge, RM
Citation: Sg. Diab et al., Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas, J CL ONCOL, 17(5), 1999, pp. 1442-1448
Risultati: 1-8 |